Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4271-4275

  Yoshinari, Tomoko ^a   Ohkubo, Mitsuru ^a   Fukasawa, Kazuhiro ^a   Egashira, Shin Ichirou ^a   Hara, Yoshikazu ^a   Matsumoto, Mami ^a   Nakai, Kiyoshi ^a   Arakawa, Hiroharu ^a   Morishima, Hajime ^a   Nishimura, Susumu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 6 N (1 HYDROXYMETHYL 2 HYDROXY)ETHYLAMINO 12,13 DIHYDRO 2,10 DIHYDROXY 13 (BETA GLUCOPYRANOSYL) 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H)DIONE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PLASMID DNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA BINDING; DNA CLEAVAGE; DNA PROTEIN COMPLEX; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033199091     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Yoshinari, T., Matsumoto, M., Arakawa, H., Okada, H., Noguchi, K., Suda, H., Okura, A., and Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)5H- indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanism of cell line-selective cytotoxicity. Cancer Res., 55: 1310-1315, 1995.
2. Arakawa, H., Iguchi, T., Morita, M., Yoshinari, T., Kojiri, K., Suda, H., and Okura, A., and Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)5H- indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-(6H)-dione (NB-506): Its potent antitumor activity in mice. Cancer Res., 55; 1316-1320, 1995.
3. Fukasawa, K., Komatani, H., Hara, Y., Suda, H., Okura, A., Nishimura, S., and Yoshinari, T. Sequence-selective DNA cleavage by topoisomerase I poison, NB-506. Int. J. Cancer, 75: 145-150, 1998.
4. Ohkubo, M., Nishimura, T., Jona, H., Honma, T., and Morishima, H. Practical synthesis of indolopyrrolocarbazoles. Tetrahedron, 52: 8099-8112, 1996.
5. Bonven, B. J., Gocke, E., and Westergaard, O. A high affinity topoisomerase I binding sequence is clustered at DNase I hypersensitive sites in Tetrahymena r-chromatin. Cell, 41: 541-551, 1985.
6. Christiansen, K., Bonven, B. J., and Westergaard, O. Mapping of sequence-specific chromatin proteins by a novel method. J. Mol. Biol., 193: 517-525, 1987.
7. Okura, A., Arakawa, H., Oka, H., Yoshinari, T., and Monden, Y. Effect of genestein on topoisomerase activity and on the growth of [VAL 12]Ha-ras-transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun., 157: 183-189, 1988.
8. Skehan, P., Storeng, R., Scudiero, D., Monks, A., MaMahon, J., Vistica, D., Warren, J. T., Bokesch, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
9. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400: 83-106, 1998.
10. Champoux, J. J. Mechanistic aspect of type I topoisomerases. In: J. C. Wang and N. R. Cozarelli (eds.), DNA Topology and Its Biological Effects, pp. 217-242. Cold Spring Harbor , NY: Cold Spring Harbor Laboratory, 1990.
11. Svejstrup, J. Q., Cristiansen, K., Gromova, I. I., Andersen, A. H., and Westergaard, O. New technique for uncoupling the cleavage and religation reaction of eucariotic topoisomerase I. J. Mol. Biol., 222: 669-678. 1991.
12. Zembower, D. E., Zhang, H., Lineswala, J. P., Kuffel, M., Aytes, S. A., and Ames, M. M. Indolocarbazole poisons of human topoisomerase I. regioisomerric analogues of ED-110. Bioorg. Med. Chem. Lett., 9: 145-150, 1999.
13. Bailly, C., Dassonneville, L., Colson, P., Houssier, C., Fukasawa, K., Nishimura, S., and Yoshinari, T. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Cancer Res., 59: 2853-2860, 1999.
14. Ohkubo, M., Kojiri, K., Kondo, H., Tanaka, S., Kawamoto, H., Nishimura, T., Nishimura, I., Yoshinari, T., Arakawa, H., Suda, H., Morishima, H., and Nishimura, S. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Bioorg. Med. Chem. Lett., 9: 1219-1224, 1999.
15. Bailly, C., Qu, X., Chaires, J. B., Colson, P., Houssier, C, Ohkubo, M., Nishimura, S., and Yoshinari, T. Topltion at F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding and topoisomerase I inhibition activities. J. Med. Chem., in press, 1999.
16. Arakawa, H., Morita, M., Kodera, T., Okura, A., Ohkubo, M., Morishima, H., and Nishimura, S. In vivo antitumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn. J. Cancer Res., in press, 1999.